English 
Chronic Kidney Disease (CKD) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00
Growth of the Prevalence CKD population will contribute to increasing sales in the CKD therapy market over our forecast period. An estimated annual growth rate of 0.4% in the Prevalent CKD population across the major pharmaceutical markets will contribute to increasing CKD therapy sales. In 2019, there were approximately 94 million prevalent cases of CKD in the major markets; we expect the number of cases will exceed 2.08 million in 2032 owing to changes in population demographics and increasing cases of CKD associated conditions such as anemia, hyperphosphatemia, secondary hyperthyroidism, diabetes kidney disease and cardiovascular patients group.
The continuous involvement of supportive treatments including renal replacement therapies for the management of dialysis dependent CKD patients will contribute to the the overall growth of the CKD therapy market. We forecast that total sales of the total current RRTs market will reach more than $13 billion by 2032.
Description
Chronic kidney disease (CKD) is a major emerging global public health problem affecting over 94 million people in G7 countries (United States, EU5 and Japan) and over 850 million people and is currently one of the most common diseases in the world. The large number of comorbidities accompanying CKD, the large number of prescribed medications, poor mental health, the high hospitalization rate, and the high mortality rate demonstrate that the patient complexity of CKD is enormous and has exceeded all other medical specialties when nine complexity markers were assessed. Although significant progress has been made in understanding the causes of kidney disease and the factors driving progression to end-stage renal disease, clinical decision support systems that tailor individual patient therapy can reduce the risk of progression and may be used to monitor and modify therapy in individual CKD patients
Chronic Kidney Disease –CKD Epidemiology
In the United States, approximately 10% of cases are on peritoneal dialysis and 60% on hemodialysis. With transplantation currently accounting for approximately 30% and home hemodialysis (HD) accounting for 2% of patients, the use of peritoneal dialysis (PD) will need to significantly increase from its current rate of ~ 10% to approach this high goal.
Chronic Kidney Disease–CKD Market Forecast
Report Highlights
- Chronic Kidney Disease–CKD Current Market Trends
- Chronic Kidney Disease–CKD Current & Forecasted Cases across the G7 Countries
- Chronic Kidney Disease–CKD Market Opportunities And Sales Potential for Agents
- Chronic Kidney Disease–CKD Patient-based Market Forecast to 2032
- Chronic Kidney Disease–CKD Untapped Business Opportunities
- Chronic Kidney Disease–CKD Product Positioning Vis-a-vis Competitors’ Products
- Chronic Kidney Disease–CKD KOLs Insight
Additional information
| Price | Single User License, 2-3 User License, Site License, Enterprise License |
|---|
Table of Contents
- Chronic Kidney Disease Disease Background
- Chronic Kidney Disease Definition
- Symptoms
- Risk Factor
- Diagnosis
- Advancing American Kidney Health (AAKH) Initiatives
- Epidemiology Estimated and Forecast to 2032
- Epidemiology Research Method & Data Sources Used
- Prevalent Cases of Chronic Kidney Disease in the United States 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in the United States 2022-2032
- Prevalent Cases of Chronic Kidney Disease in Germany 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Germany 2022-2032
- Prevalent Cases of Chronic Kidney Disease in France 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in France 2022-2032
- Prevalent Cases of Chronic Kidney Disease in Italy 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Italy 2022-2032
- Prevalent Cases of Chronic Kidney Disease in Spain 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Spain 2022-2032
- Prevalent of Chronic Kidney Disease in the United Kingdom 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in the United Kingdom 2022-2032
- Prevalent Cases of Chronic Kidney Disease in Japan 2022-2032
- Cases of Chronic Kidney Disease by Dialysis Dependency & Comorbidities in Japan 2022-2032
- Epidemiology Research Method & Data Sources Used
- Patients on Dialysis per country
- Patients on Dialysis per country by Treatment Modality
- Current Unmet Needs in Chronic Kidney Disease
- Current Treatment Paradigm
- Treatment guidelines for Chronic Kidney Disease
- Current Approved Treatments for CKD
- Reimbursement Scenario in Chronic Kidney Disease
- Dialysis modality distribution
- Global Reimbursement of Different Dialysis Strategies
- Reimbursement by Self-care hemodialysis, Home hemodialysis, CAPD, APD & Hospital hemodialysis
- Reimbursement Scenarios in the Belgium, Germany, The Netherlands, United Kingdom, France, United States & Ontario, Canada, Japan and Other countries.
- Primary Findings
- Emerging Therapies Chapters
- daprodustat (GSK)
- Canagliflozin (J&J/Mitsubishi Tanabe Pharma )
- darbepoetin alfa (Kissei Pharma/ JCR Pharma)
- ferumoxytol (AMAG Pharmaceuticals)
- Roxadustat (FibroGen/ Astellas Pharma)
- vadadustat (Akebia Therapeutics)
- Tenapanor (Ardelyx)
- Bardoxolone methyl (Reata Pharmaceuticals, Inc)
- Dapagliflozin (AstraZeneca)
- Empagliflozin (Boehringer Ingelheim/ Eli Lilly)
- TRC-101 (Tricida Inc.)
- PDprotec (Zytoprotec)
- Total Market Forecast
- Key Summary Findings
- G7 total Market for Chronic Kidney Disease 2022-2032 (USD Million)
- G7 total Market for Chronic Kidney Disease by Therapies 2022-2032 (USD Million)
- Key Summary Findings
- Market Forecast by Country
- United States
- United States Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- Germany
- Germany Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- France
- France Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- Italy
- Italy Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- Spain
- Spain Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- United Kingdom
- United Kingdom Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- Japan
- Japan Market for Chronic Kidney Disease 2022-2032 (USD Million)
- United States Market for CKD by Segments (Anemia, Secondary Hyperthyroidism, Hyperphosphatemia & CVD-CKD risk group) & Therapies 2022-2032 (USD Million)
- United States
- Market Drivers & Barriers
Sample Enquiry
Related products
-
HER2-Low Gastric / Gastroesophageal Junction (GEJ) Adenocarcinoma | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
$6,989.00 – $20,967.00Select optionsAccording to Mellalta Meets Analyst’s most recent estimate, the HER2-Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma therapeutics market was worth US$ Billion in 2023 and is predicted to grow at a XX% CAGR to reach US$ Billion by 2034.
-
Obstructive Sleep Apnea (OSA) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00Select optionsGrowth of the Prevalence OSA population will contribute to increasing sales in the OSA therapy market over our forecast period. The increase in the number of patients with obstructive sleep apnea across the globe will be driving the market of OSA. According to a study conducted by the World Health Organization (WHO), the global prevalence of sleep apnea is around 100 million people. In the U.S. alone, the number of people with OSA is around 42 million. One out of five adults in the U.S. has mild OSA, while one out of 15 has moderate to severe OSA. The number of cases with OSA is expected to increase during our forecast period, primarily due to the increasing Prevalence of sleep-related disorders. This is projected to drive the OSA market from 2022 to 2032
-
High grade intraepithelial lesion (HSIL) | Primary Research (KOL’s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
$6,989.00 – $20,967.00 Select options -
HER2-Low Metastatic Breast Cancer (mBC) | Primary Research (KOL’s Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
$6,989.00 – $20,967.00Select optionsAccording to Mellalta Meets Analyst’s most recent estimate, the HER2-Low Metastatic Breast Cancer therapeutics market was worth US$ Billion in 2023 and is predicted to grow at a XX% CAGR to reach US$ Billion by 2034.